jnj-68284528
Cell therapyexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Jun 29, 2018 (NCT03548207)
Timeline
Indications
Studied for
Mechanism of action
- BCMAImmunity, passive
BCMA immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05666700 | Phase 1 | Feb 28, 2023 | Janssen Pharmaceutica NV, Peter MacCallum Cancer Centre |
| NCT04181827 | Phase 3 | Feb 20, 2020 | Janssen Pharmaceutica NV |
| NCT04133636 | Phase 2 | Oct 23, 2019 | Janssen Pharmaceutica NV |
| NCT03548207 | Phase 1/Phase 2 (Phase 2) | Jun 29, 2018 | Johnson and Johnson |
| NCT04452994 | N/A | — | Janssen Pharmaceutica NV |
| NCT05346835 | N/A | — | Janssen Pharmaceutica NV |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 5 | 4 | 4 | 2019 |
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2018 |
| Peter MacCallum Cancer Centre | Academic/Hospital | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1